For Providers
- Solutions
  - MIPD for Providers Explore our full solution for Bayesian model-informed dosing
  - Future of Pharmacy Learn what's next for AI in health tech, and why architecture matters
- Products
For Life Sciences
- Overview
  - InsightRX for Life Sciences Explore our solution for biopharma and clinical trial use
- Products
  - Nova for Life Sciences Precision dosing app for clinical trial use
  - Astra for Life Sciences AI-native environment for PK/PD modeling and simulation
Platform
Resources
Company
- About
- Press

Featured Post

New consensus guidance for beta-lactam dose individualization

Home
Resources
Blog

Recent Posts

Thought leadership and product updates from the InsightRX team.

Filter

Search Author

Tags

Thought Leadership Sep 21, 2025

Model-Informed Precision Dosing for Conditioning Regimens: Busulfan, Fludarabine, ATG, and More

Thought Leadership Feb 24, 2025

From Empiric to Precise: Transforming Tacrolimus Dosing and Monitoring with MIPD

Thought Leadership Sep 7, 2022

The Evolution of Therapeutic Drug Monitoring for Tacrolimus

Product Innovation Mar 25, 2022

Roadmap Preview: Bringing Precision Dosing To New Therapeutic Areas

Thought Leadership Jul 18, 2018

The Right Dose: How Pharmacy Researchers Are Making Medicine More Precise

Maximize therapeutic success
with precision medicine.

What We Do

For Providers

Nova (Bayesian Dosing)
Apollo (Clinical Analytics)
Drug Modules

For Life Sciences

Nova (MIPD for Clinical Trials)
Astra (AI-Powered Clin Pharm)
Companion Applications

How We Do It

Platform

Continuous Learning
Integrations
Security & Regulatory
Success & Support

Science

Data Science
Scientific Publications

Information

Resources

Success Stories
White Papers
Publications Using InsightRX
How to Cite InsightRX

Blog

All Posts
Product Innovation
Thought Leadership

About

Our Story
Leadership
Advisory Board
Our Customers
Press Releases
Media
Careers
Contact

InsightRX Nova is HITRUST CSF r2 certified, CE marked, and 21 CFR Part 11 compliant. Our quality management, risk management, software lifecycle, and usability engineering processes conform to ISO 13485, IEC 62304, ISO 14971, IEC 62366-1, and IEC 82304-1.

InsightRX Nova is not considered to be a medical device in the U.S. and has not been submitted to the U.S. Food and Drug Administration for review or clearance.

740-05000-REC-01 · 08/2025

548 Market Street
#88083
San Francisco, CA 94104

© 2026 InsightRX, Inc. All rights reserved.

Privacy Policy Cookie Preferences